{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:22:15Z","timestamp":1780446135207,"version":"3.54.1"},"reference-count":78,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_ijamh-2025-0163_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Hodgkin\u2019s Lymphoma (HL) is the most common malignancy among Adolescents and Young Adults (AYAs). Although survival rates are excellent, two thirds of survivors experience physical and psychosocial late effects that can emerge years or decades after treatment significantly impacting quality of life. As care priorities shift from cure to survivorship, it is essential that health care professionals (HCPs)\u2014across oncology, primary care, mental health, and general medical services\u2014are equipped to recognise, anticipate, and respond to these long-term consequences. This narrative review examined the evolution of HL treatment in AYAs and explored how these changes influence late-effect risks, with the aim of informing HCP vigilance and clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_ijamh-2025-0163_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A narrative review of clinical studies, guidelines, and review literature was conducted to evaluate changes in radiotherapy and chemotherapy strategies, including treatment de-escalation, risk-adapted regimens, and advances in radiotherapy targeting. Literature and long-term population studies describing late effects, such as secondary malignancies, cardiopulmonary toxicity, endocrine disorders, and psychosocial challenges, was synthesised to identify patterns of late effects presenting in this group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_ijamh-2025-0163_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Findings demonstrate a clear evolution toward less intensive and more individualised treatments; however, substantial late-effect risks persist. Limited long-term outcome data reflective of contemporary treatment approaches further complicate timely recognition of these late effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_ijamh-2025-0163_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Despite major therapeutic advances, AYAs remain vulnerable to long-term and late-presenting consequences of HL treatment. All HCPs who may encounter these individuals must maintain vigilant for late effects and deliver proactive, informed care that supports their sustained physical and psychological well-being.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/ijamh-2025-0131","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T05:57:46Z","timestamp":1763704666000},"page":"103-110","source":"Crossref","is-referenced-by-count":1,"title":["From cure to care\u2013understanding long-term health risks after Hodgkin\u2019s lymphoma treatment in adolescents and young adults"],"prefix":"10.1515","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8038-3651","authenticated-orcid":false,"given":"Maeve","family":"Kearney","sequence":"first","affiliation":[{"name":"8809 Applied Radiation Therapy Trinity, Discipline of Radiation Therapy, Trinity College Dublin , Dublin 2 , Ireland"},{"name":"Trinity St James\u2019s Cancer Institute, St. James\u2019s Hospital , Dublin 8 , Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Faithfull","sequence":"additional","affiliation":[{"name":"8809 Applied Radiation Therapy Trinity, Discipline of Radiation Therapy, Trinity College Dublin , Dublin 2 , Ireland"},{"name":"School of Cancer & Pharmaceutical Sciences , King\u2019s College London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Leech","sequence":"additional","affiliation":[{"name":"8809 Applied Radiation Therapy Trinity, Discipline of Radiation Therapy, Trinity College Dublin , Dublin 2 , Ireland"},{"name":"Trinity St James\u2019s Cancer Institute, St. James\u2019s Hospital , Dublin 8 , Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"key":"2026050116285907848_j_ijamh-2025-0131_ref_001","doi-asserted-by":"crossref","unstructured":"Barr, RD, Ferrari, A, Ries, L, Whelan, J, Bleyer, WA. Cancer in adolescents and young adults: a narrative review of the current status and a view of the future. JAMA Pediatr 2016;170:495\u2013501. https:\/\/doi.org\/10.1001\/jamapediatrics.2015.4689.","DOI":"10.1001\/jamapediatrics.2015.4689"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_002","unstructured":"(NCCP), H.N.C.C.P. Framework for the care and support of adolescent and young adults (AYA) with cancer in Ireland 2021 to 2026. 2022 [cited 2022\u00a031\/05\/22]; Available from: https:\/\/www.hse.ie\/eng\/services\/publications\/framework-for-the-care-and-support-of-adolescent-and-young-adults-in-ireland.pdf."},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_003","doi-asserted-by":"crossref","unstructured":"Hochberg, J, Waxman, IM, Kelly, KM, Morris, E, Cairo, MS. Adolescent non-hodgkin lymphoma and hodgkin lymphoma: state of the science. Br J Haematol 2009;144:24\u201340. https:\/\/doi.org\/10.1111\/j.1365-2141.2008.07393.x.","DOI":"10.1111\/j.1365-2141.2008.07393.x"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_004","doi-asserted-by":"crossref","unstructured":"Toukam, M, Boni, JP, Hamadani, M, Caimi, PF, Cruz, HG, Wuerthner, J, et al.. Exposure\u2013response analysis of camidanlumab tesirine in patients with relapsed or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma. Cancer Chemother Pharmacol 2023;91:1\u201312. https:\/\/doi.org\/10.1007\/s00280-022-04487-3.","DOI":"10.1007\/s00280-022-04487-3"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_005","doi-asserted-by":"crossref","unstructured":"Herbertson, R, Hancock, B. Hodgkin lymphoma in adolescents. Cancer Treat Rev 2005;31:339\u201360. https:\/\/doi.org\/10.1016\/j.ctrv.2005.04.011.","DOI":"10.1016\/j.ctrv.2005.04.011"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_006","doi-asserted-by":"crossref","unstructured":"Belsky, JA, Hochberg, J, Giulino-Roth, L. Diagnosis and management of hodgkin lymphoma in children, adolescents, and young adults. Best Pract Res Clin Haematol 2023;36:101445. https:\/\/doi.org\/10.1016\/j.beha.2023.101445.","DOI":"10.1016\/j.beha.2023.101445"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_007","doi-asserted-by":"crossref","unstructured":"Khanna, P, Malluru, N, Pyada, R, Gupta, M, Akkihal, K, Varkey, TC, et al.. Fever of unknown origin: the workup and diagnosis of pel-ebstein fever. Cureus 2022;14. https:\/\/doi.org\/10.7759\/cureus.21959.","DOI":"10.7759\/cureus.21959"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_008","doi-asserted-by":"crossref","unstructured":"Oyake, M, Suenobu, S, Miyawaki, M, Ohchi, Y, Ihara, K. Airway emergencies due to anterior mediastinal T-lymphoblastic lymphoma managed with planned extracorporeal membrane oxygenation and endotracheal stent: a case report and literature review. Cureus 2022;14. https:\/\/doi.org\/10.7759\/cureus.21799.","DOI":"10.7759\/cureus.21799"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_009","doi-asserted-by":"crossref","unstructured":"Cheson, BD, Fisher, RI, Barrington, SF, Cavalli, F, Schwartz, LH, Zucca, E, et al.. Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-Hodgkin lymphoma: the lugano classification. J\u00a0Clin Oncol 2014;32:3059\u201367. https:\/\/doi.org\/10.1200\/jco.2013.54.8800.","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_010","doi-asserted-by":"crossref","unstructured":"Borchmann, P, Goergen, H, Kobe, C, Lohri, A, Greil, R, Eichenauer, DA, et al.. PET-guided treatment in patients with advanced-stage hodgkin\u2019s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin study group. Lancet 2017;390:2790\u2013802. https:\/\/doi.org\/10.1016\/s0140-6736(17)32134-7.","DOI":"10.1016\/S0140-6736(17)32134-7"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_011","doi-asserted-by":"crossref","unstructured":"Canellos, GP, Anderson, JR, Propert, KJ, Nissen, N, Cooper, MR, Henderson, ES, et al.. Chemotherapy of advanced Hodgkin\u2019s disease with MOPP, ABVD, or MOPP alternating with ABVD. N\u00a0Engl J Med 1992;327:1478\u201384. https:\/\/doi.org\/10.1056\/nejm199211193272102.","DOI":"10.1056\/NEJM199211193272102"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_012","doi-asserted-by":"crossref","unstructured":"Diehl, V, Behringer, K. Could BEACOPP be the new standard for the treatment of advanced Hodgkin\u2019s lymphoma (HL)?. Cancer Invest 2006;24:713\u201317. https:\/\/doi.org\/10.1080\/07357900600981380.","DOI":"10.1080\/07357900600981380"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_013","doi-asserted-by":"crossref","unstructured":"Specht, L, Yahalom, J, Illidge, T, Berthelsen, AK, Constine, LS, Eich, HT, et al.. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys 2014;89:854\u201362. https:\/\/doi.org\/10.1016\/j.ijrobp.2013.05.005.","DOI":"10.1016\/j.ijrobp.2013.05.005"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_014","doi-asserted-by":"crossref","unstructured":"Pusey, WA. Cases of sarcoma and of hodgkin\u2019s disease treated by exposures to x-rays\u2014a preliminary report. J\u00a0Am Med Assoc 1902:166\u20139. https:\/\/doi.org\/10.1001\/jama.1902.62480030024001h. XXXVIII.","DOI":"10.1001\/jama.1902.62480030024001h"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_015","unstructured":"Kaplan, HS. Hodgkin\u2019s disease. USA: Harvard University Press; 1980."},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_016","doi-asserted-by":"crossref","unstructured":"Bagshaw, MA, Henry Seymour Kaplan, MD (1918-1984), Maureen lyles D\u2019ambrogio professor, department of radiology. Director, cancer biology research laboratory, stanford university. CA Cancer J Clin 1984;34:208\u20139.","DOI":"10.1002\/1097-0142(19850501)55:9+<2035::AID-CNCR2820551402>3.0.CO;2-U"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_017","doi-asserted-by":"crossref","unstructured":"Tarbell, NJ, Mauch, P, Gelber, R, Weinstein, H. Sex differences in risk of second malignant tumours after Hodgkin\u2019s disease in childhood. Lancet 1993;341:1428\u201332. https:\/\/doi.org\/10.1016\/0140-6736(93)90880-p.","DOI":"10.1016\/0140-6736(93)90880-P"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_018","doi-asserted-by":"crossref","unstructured":"Hellman, S, Mauch, P, Goodman, RL, Rosenthal, DS, Moloney, WC. The place of radiation therapy in the treatment of Hodgkin\u2019s disease. Cancer 1978;42:971\u20138. https:\/\/doi.org\/10.1002\/1097(0142)197808-42:2+<971::aid-cncr2820420720>3.0.co;2-i.","DOI":"10.1002\/1097-0142(197808)42:2+<971::AID-CNCR2820420720>3.0.CO;2-I"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_019","unstructured":"Kaplan, HS, Stewart, JR. Complications of intensive megavoltage radiotherapy for Hodgkin\u2019s disease 1, 2. USA: National Cancer Institute Monograph; 1973:439 p."},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_020","doi-asserted-by":"crossref","unstructured":"Dubray, B, Henry-Amar, M, Meerwaldt, JH, Noordijk, EM, Dixon, DO, Cosset, JM, et al.. Radiation-induced lung damage after thoracic irradiation for Hodgkin\u2019s disease: the role of fractionation. Radiother Oncol 1995;36:211\u201317. https:\/\/doi.org\/10.1016\/0167-8140(95)01606-h.","DOI":"10.1016\/0167-8140(95)01606-H"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_021","doi-asserted-by":"crossref","unstructured":"Mauch, P, Somers, R. Controversies in the use of diagnostic staging laparotomy and splenectomy in the management of Hodgkin\u2019s disease. Ann Oncol 1992;1:S41-3.","DOI":"10.1093\/annonc\/3.suppl_4.S41"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_022","doi-asserted-by":"crossref","unstructured":"Mill, WB, Baglan, RJ, Kurichety, P, Prasad, S, Lee, JY, Moller, R, et al.. Symptomatic radiation-induced pericarditis in Hodgkin\u2019s disease. Int J Radiat Oncol Biol Phys 1984;10:2061\u20135. https:\/\/doi.org\/10.1016\/0360-3016(84)90203-7.","DOI":"10.1016\/0360-3016(84)90203-7"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_023","doi-asserted-by":"crossref","unstructured":"van Leeuwen, FE, Ng, AK. Long-term risk of second malignancy and cardiovascular disease after Hodgkin lymphoma treatment. Hematology 2016;2016:323\u201330. https:\/\/doi.org\/10.1182\/asheducation-2016.1.323.","DOI":"10.1182\/asheducation-2016.1.323"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_024","doi-asserted-by":"crossref","unstructured":"Henry-Amar, M, Joly, F. Late complications after Hodgkin\u2019s disease. Ann Oncol 1996;7:S115\u201326. https:\/\/doi.org\/10.1093\/annonc\/7.suppl_4.s115.","DOI":"10.1093\/annonc\/7.suppl_4.S115"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_025","doi-asserted-by":"crossref","unstructured":"Bhatia, S, Yasui, Y, Robison, LL, Birch, JM, Bogue, MK, Diller, L, et al.. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin\u2019s disease: report from the late effects study group. J\u00a0Clin Oncol 2003;21:4386\u201394. https:\/\/doi.org\/10.1200\/jco.2003.11.059.","DOI":"10.1200\/JCO.2003.11.059"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_026","doi-asserted-by":"crossref","unstructured":"Valagussa, P, Santoro, A, Fossati-Bellani, F, Banfi, A, Bonadonna, G. Second acute leukemia and other malignancies following treatment for Hodgkin\u2019s disease. J\u00a0Clin Oncol 1986;4:830\u20137. https:\/\/doi.org\/10.1200\/jco.1986.4.6.830.","DOI":"10.1200\/JCO.1986.4.6.830"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_027","doi-asserted-by":"crossref","unstructured":"Tucker, MA, Coleman, C, Cox, R, Varghese, A, Rosenberg, S. Risk of second cancers after treatment for Hodgkin\u2019s disease. N\u00a0Engl J Med 1988;318:76\u201381. https:\/\/doi.org\/10.1056\/nejm198801143180203.","DOI":"10.1056\/NEJM198801143180203"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_028","unstructured":"Boivin, J-F, Hutchison, GB, Lyden, M, Godbold, J, Chorosh, J, Schottenfeld, D, et al.. Second primary cancers following treatment of Hodgkin\u2019s disease. J\u00a0Natl Cancer Inst 1984;72:233\u201341."},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_029","doi-asserted-by":"crossref","unstructured":"Santoro, A, Bonadonna, G, Bonfante, V, Valagussa, P. Alternating drug combinations in the treatment of advanced Hodgkin\u2019s disease. N\u00a0Engl J Med 1982;306:770\u20135. https:\/\/doi.org\/10.1056\/nejm198204013061303.","DOI":"10.1056\/NEJM198204013061303"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_030","doi-asserted-by":"crossref","unstructured":"Rosenberg, SA, Kaplan, HS. The evolution and summary results of the stanford randomized clinical trials of the management of Hodgkin\u2019s disease: 1962-1984. Int J Radiat Oncol Biol Phys 1985;11:5\u201322. https:\/\/doi.org\/10.1016\/0360-3016(85)90357-8.","DOI":"10.1016\/0360-3016(85)90357-8"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_031","doi-asserted-by":"crossref","unstructured":"Boice, J, JD, Monson, RR. Breast cancer in women after repeated fluoroscopic examinations of the chest. J\u00a0Natl Cancer Inst 1977;59:823\u201332. https:\/\/doi.org\/10.1093\/jnci\/59.3.823.","DOI":"10.1093\/jnci\/59.3.823"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_032","doi-asserted-by":"crossref","unstructured":"Samant, R, Alomary, I, Alsaeed, E, Al-jasir, B, Bence-Bruckler, I, Cross, P, et al.. Comparison of favorable early-stage Hodgkin\u2019s lymphoma treatments: a single-institution review. Int J Radiat Oncol Biol Phys 2010;76:1166\u201370. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.03.070.","DOI":"10.1016\/j.ijrobp.2009.03.070"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_033","doi-asserted-by":"crossref","unstructured":"Yahalom, J, Mauch, P. The involved field is back: issues in delineating the radiation field in Hodgkin\u2019s disease. Ann Oncol 2002;13:79\u201383. https:\/\/doi.org\/10.1093\/annonc\/13.s1.79.","DOI":"10.1093\/annonc\/13.S1.79"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_034","doi-asserted-by":"crossref","unstructured":"D\u00fchmke, E, Diehl, V, Loeffler, M, Mueller, RP, Ruehl, U, Willich, N, et al.. Randomized trial with early-stage Hodgkin\u2019s disease testing 30\u00a0Gy vs. 40\u00a0Gy extended field radiotherapy alone. Int J Radiat Oncol Biol Phys 1996;36:305\u201310. https:\/\/doi.org\/10.1016\/s0360-3016(96)00333-1.","DOI":"10.1016\/S0360-3016(96)00333-1"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_035","doi-asserted-by":"crossref","unstructured":"Zittoun, R, Audebert, A, Hoerni, B, Bernadou, A, Krulik, M, Rojouan, J, et al.. Extended versus involved fields irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkin\u2019s disease. J\u00a0Clin Oncol 1985;3:207\u201314. https:\/\/doi.org\/10.1200\/jco.1985.3.2.207.","DOI":"10.1200\/JCO.1985.3.2.207"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_036","doi-asserted-by":"crossref","unstructured":"Ferm\u00e9, C, Eghbali, H, Meerwaldt, JH, Rieux, C, Bosq, J, Berger, F, et al.. Chemotherapy plus involved-field radiation in early-stage Hodgkin\u2019s disease. N\u00a0Engl J Med 2007;357:1916\u201327. https:\/\/doi.org\/10.1056\/nejmoa064601.","DOI":"10.1056\/NEJMoa064601"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_037","doi-asserted-by":"crossref","unstructured":"Engert, A, Pl\u00fctschow, A, Eich, HT, Lohri, A, D\u00f6rken, B, Borchmann, P, et al.. Reduced treatment intensity in patients with early-stage Hodgkin\u2019s lymphoma. N\u00a0Engl J Med 2010;363:640\u201352. https:\/\/doi.org\/10.1056\/nejmoa1000067.","DOI":"10.1056\/NEJMoa1000067"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_038","doi-asserted-by":"crossref","unstructured":"Pommier, P, Dussart, S, Girinsky, T, Chabaud, S, Lagrange, JL, Nguyen, TD, et al.. Impact of 18F-fluoro-2-deoxyglucose positron emission tomography on treatment strategy and radiotherapy planning for stage I\u2013II Hodgkin disease: a prospective multicenter study. Int J Radiat Oncol Biol Phys 2011;79:823\u20138. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.11.048.","DOI":"10.1016\/j.ijrobp.2009.11.048"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_039","doi-asserted-by":"crossref","unstructured":"Johnson, P, Federico, M, Kirkwood, A, Foss\u00e5, A, Berkahn, L, Carella, A, et al.. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma. N\u00a0Engl J Med 2016;374:2419\u201329. https:\/\/doi.org\/10.1056\/nejmoa1510093.","DOI":"10.1056\/NEJMoa1510093"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_040","doi-asserted-by":"crossref","unstructured":"Engert, A, Haverkamp, H, Kobe, C, Markova, J, Renner, C, Ho, A, et al.. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin\u2019s lymphoma (HD15 trial): a randomised, open-label, phase 3\u00a0non-inferiority trial. Lancet 2012;379:1791\u20139. https:\/\/doi.org\/10.1016\/s0140-6736(11)61940-5.","DOI":"10.1016\/S0140-6736(11)61940-5"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_041","doi-asserted-by":"crossref","unstructured":"Wirth, A, Mikhaeel, NG, Aleman, BM, Pinnix, CC, Constine, LS, Ricardi, U, et al.. Involved site radiation therapy in adult lymphomas: an overview of international lymphoma radiation oncology group guidelines. Int J Radiat Oncol Biol Phys 2020;107:909\u201333. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.03.019.","DOI":"10.1016\/j.ijrobp.2020.03.019"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_042","doi-asserted-by":"crossref","unstructured":"Mazonakis, M, Lyraraki, E, Damilakis, J. Second cancer risk assessments after involved-site radiotherapy for mediastinal Hodgkin lymphoma. Med Phys 2017;44:3866\u201374. https:\/\/doi.org\/10.1002\/mp.12327.","DOI":"10.1002\/mp.12327"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_043","doi-asserted-by":"crossref","unstructured":"Engert, A, Franklin, J, Eich, HT, Brillant, C, Sehlen, S, Cartoni, C, et al.. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin\u2019s lymphoma: final results of the GHSG HD7 trial. J\u00a0Clin Oncol 2007;25:3495\u2013502. https:\/\/doi.org\/10.1200\/jco.2006.07.0482.","DOI":"10.1200\/JCO.2006.07.0482"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_044","unstructured":"Engert, A. Involved field (IF) radiotherapy is as effective as extended field (EF) radiotherapy after 2 cycles of COPP\/ABVD in patients (pts) with intermediate-stage Hodgkin\u2019s disease (HD): a randomized multicenter study. In: Blood. Washington, USA: Amer Soc Hematology; 2001."},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_045","doi-asserted-by":"crossref","unstructured":"Borchmann, P, Diehl, V, Goergen, H, Mueller, H, Mueller, RP, Eich, HT, et al.. Combined modality treatment with intensified chemotherapy and dose-reduced involved field radiotherapy in patients with early unfavourable Hodgkin lymphoma (HL): final analysis of the German Hodgkin study group (GHSG) HD11 trial. Blood 2009;114:717. https:\/\/doi.org\/10.1182\/blood.v114.22.717.717.","DOI":"10.1182\/blood.V114.22.717.717"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_046","doi-asserted-by":"crossref","unstructured":"Bonadonna, G, Bonfante, V, Viviani, S, Di Russo, A, Villani, F, Valagussa, P, et al.. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin\u2019s disease: long-term results. J\u00a0Clin Oncol 2004;22:2835\u201341. https:\/\/doi.org\/10.1200\/jco.2004.12.170.","DOI":"10.1200\/JCO.2004.12.170"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_047","doi-asserted-by":"crossref","unstructured":"Raemaekers, J, Burgers, M, Henry-Amar, M, Pinna, A, Mandard, A, Monfardini, S, et al.. Patients with stage III\/IV Hodgkin\u2019s disease in partial remission after MOPP\/ABV chemotherapy have excellent prognosis after additional involved-field radiotherapy: interim results from the ongoing EORTC-LCG and GPMC phase III trial. The EORTC Lymphoma cooperative group and groupe pierre-et-marie-curie. Ann Oncol 1997;8:111\u20134. https:\/\/doi.org\/10.1093\/annonc\/8.suppl_1.s111.","DOI":"10.1093\/annonc\/8.suppl_1.S111"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_048","doi-asserted-by":"crossref","unstructured":"Bigenwald, C, Galimard, JE, Quero, L, Cabannes-Hamy, A, Thieblemont, C, Boissel, N, et al.. Hodgkin lymphoma in adolescent and young adults: insights from an adult tertiary single-center cohort of 349 patients. Oncotarget 2017;8:80073\u201382. https:\/\/doi.org\/10.18632\/oncotarget.20684.","DOI":"10.18632\/oncotarget.20684"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_049","doi-asserted-by":"crossref","unstructured":"Parsons, HM, Harlan, LC, Schmidt, S, Keegan, TH, Lynch, CF, Kent, EE, et al.. Who treats adolescents and young adults with cancer? A report from the AYA HOPE study. J\u00a0Adolesc Young Adult Oncol 2015;4:141\u201350. https:\/\/doi.org\/10.1089\/jayao.2014.0041.","DOI":"10.1089\/jayao.2014.0041"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_050","doi-asserted-by":"crossref","unstructured":"Coccia, PF, Pappo, AS, Altman, J, Bhatia, S, Borinstein, SC, Flynn, J, et al.. Adolescent and young adult oncology, version 2.2014. J\u00a0Natl Compr Cancer Netw 2014;12:21\u201332. https:\/\/doi.org\/10.6004\/jnccn.2014.0004.","DOI":"10.6004\/jnccn.2014.0004"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_051","doi-asserted-by":"crossref","unstructured":"Lew-Derivry, L, Brice, P, Bigenwald, C, Landman-Parker, J, Leblanc, T, Chevillon, F, et al.. Should adolescents and young adults with hodgkin lymphoma be treated as children or adults? Blood 2022;140:1749\u201350. https:\/\/doi.org\/10.1182\/blood-2022-157046.","DOI":"10.1182\/blood-2022-157046"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_052","doi-asserted-by":"crossref","unstructured":"Yung, L, Smith, P, Hancock, B, Hoskin, P, Gilson, D, Vernon, C, et al.. Long term outcome in adolescents with Hodgkin\u2019s lymphoma: poor results using regimens designed for adults. Leuk Lymphoma 2004;45:1579\u201385. https:\/\/doi.org\/10.1080\/1042819042000209404.","DOI":"10.1080\/1042819042000209404"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_053","doi-asserted-by":"crossref","unstructured":"Eichenauer, DA, Bredenfeld, H, Haverkamp, H, M\u00fcller, H, Franklin, J, Fuchs, M, et al.. Hodgkin\u2019s lymphoma in adolescents treated with adult protocols: a report from the German Hodgkin study group. J\u00a0Clin Oncol 2009;27:6079\u201385. https:\/\/doi.org\/10.1200\/jco.2008.20.2655.","DOI":"10.1200\/JCO.2008.20.2655"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_054","doi-asserted-by":"crossref","unstructured":"Hapgood, G, Zheng, Y, Sehn, LH, Villa, D, Klasa, R, Gerrie, AS, et al.. Evaluation of the risk of relapse in classical Hodgkin lymphoma at event-free survival time points and survival comparison with the general population in British Columbia. J\u00a0Clin Oncol 2016;34:2493\u2013500. https:\/\/doi.org\/10.1200\/jco.2015.65.4194.","DOI":"10.1200\/JCO.2015.65.4194"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_055","doi-asserted-by":"crossref","unstructured":"Kahn, JM, Kelly, KM. Adolescent and young adult Hodgkin lymphoma: raising the bar through collaborative science and multidisciplinary care. Pediatr Blood Cancer 2018;65:e27033. https:\/\/doi.org\/10.1002\/pbc.27033.","DOI":"10.1002\/pbc.27033"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_056","doi-asserted-by":"crossref","unstructured":"Adams, SC, Herman, J, Lega, IC, Mitchell, L, Hodgson, D, Edelstein, K, et al.. Young adult cancer survivorship: recommendations for patient follow-up, exercise therapy, and research. JNCI Cancer Spectr 2020;5. https:\/\/doi.org\/10.1093\/jncics\/pkaa099.","DOI":"10.1093\/jncics\/pkaa099"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_057","doi-asserted-by":"crossref","unstructured":"Greenzang, KA, Fasciano, KM, Block, SD, Mack, JW. Early information needs of adolescents and young adults about late effects of cancer treatment. Cancer 2020;126:3281\u20138. https:\/\/doi.org\/10.1002\/cncr.32932.","DOI":"10.1002\/cncr.32932"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_058","doi-asserted-by":"crossref","unstructured":"Woodward, E, Jessop, M, Glaser, A, Stark, D. Late effects in survivors of teenage and young adult cancer: does age matter? Ann Oncol 2011;22:2561\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdr044.","DOI":"10.1093\/annonc\/mdr044"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_059","doi-asserted-by":"crossref","unstructured":"Verginadis, II, Citrin, DE, Ky, B, Feigenberg, SJ, Georgakilas, AG, Hill-Kayser, CE, et al.. Radiotherapy toxicities: mechanisms, management, and future directions. Lancet 2025;45:338\u201352. https:\/\/doi.org\/10.1016\/s0140-6736(24)02319-5.","DOI":"10.1016\/S0140-6736(24)02319-5"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_060","doi-asserted-by":"crossref","unstructured":"Koo, E, Henderson, MA, Dwyer, M, Skandarajah, AR. Radiation-associated thyroid cancer surveillance and management in a cohort of late effects patients. World J Surg 2020;44:3028\u201335. https:\/\/doi.org\/10.1007\/s00268-020-05547-6.","DOI":"10.1007\/s00268-020-05547-6"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_061","unstructured":"Omar, M, Nor Afiah, MZ, Ahmad, N, Tan, KA, Murallitharan, M. Effectiveness of an independent physical activity programme in improving physical activity amongst breast and colorectal cancer survivors: study protocol for a randomized controlled trial. Med J Malaysia 2021;76:480\u20137."},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_062","doi-asserted-by":"crossref","unstructured":"Abrahao, R, Brunson, AM, Kahn, JM, Li, Q, Rosenberg, AS, Wun, T, et al.. Second primary malignancy risk among HIV-uninfected and HIV-infected survivors of Hodgkin lymphoma: a 30-year Follow-up population-based study. Blood 2020;136:15\u201317. https:\/\/doi.org\/10.1182\/blood-2020-137728.","DOI":"10.1182\/blood-2020-137728"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_063","doi-asserted-by":"crossref","unstructured":"Lo, AC, Chen, B, Samuel, V, Savage, KJ, Freeman, C, Goddard, K, et al.. Late effects in survivors treated for lymphoma as adolescents and young adults: a population-based analysis. J\u00a0cancer survivorship: res pract 2021;15:837\u201346. https:\/\/doi.org\/10.1007\/s11764-020-00976-7.","DOI":"10.1007\/s11764-020-00976-7"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_064","doi-asserted-by":"crossref","unstructured":"Marr, KC, Simkin, J, Lo, AC, Connors, JM, Gerrie, AS, Villa, D, et al.. Cardiac morbidity in adolescents and young adult survivors of Hodgkin lymphoma. Blood 2020;136:18\u201319. https:\/\/doi.org\/10.1182\/blood-2020-136454.","DOI":"10.1182\/blood-2020-136454"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_065","doi-asserted-by":"crossref","unstructured":"Keegan, TH, Lichtensztajn, DY, Kato, I, Kent, EE, Wu, XC, West, MM, et al.. Unmet adolescent and young adult cancer survivors information and service needs: a population-based cancer registry study. J\u00a0cancer survivorship 2012;6:239\u201350. https:\/\/doi.org\/10.1007\/s11764-012-0219-9.","DOI":"10.1007\/s11764-012-0219-9"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_066","doi-asserted-by":"crossref","unstructured":"Hussey, C, Hanbridge, M, Dowling, M, Gupta, A. Cancer survivorship: understanding the patients\u2019 journey and perspectives on post-treatment needs. BMC Sports Science, Medicine and Rehabilitation 2024;16:82. https:\/\/doi.org\/10.1186\/s13102-024-00864-y.","DOI":"10.1186\/s13102-024-00864-y"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_067","unstructured":"America Co.Qo.HCi. Crossing the quality chasm: a new health system for the 21st century. USA: National Academies Press; 2001."},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_068","doi-asserted-by":"crossref","unstructured":"Janssen, SHM, van der Graaf, WTA, van der Meer, DJ, Manten-Horst, E, Husson, O. Adolescent and young adult (AYA) cancer survivorship practices: an overview. Cancers 2021;13:4847. https:\/\/doi.org\/10.3390\/cancers13194847.","DOI":"10.3390\/cancers13194847"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_069","doi-asserted-by":"crossref","unstructured":"Sisk, BA, Canavera, K, Sharma, A, Baker, JN, Johnson, L. Ethical issues in the care of adolescent and young adult oncology patients. Pediatr Blood Cancer 2019;66. https:\/\/doi.org\/10.1002\/pbc.27608.","DOI":"10.1002\/pbc.27608"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_070","doi-asserted-by":"crossref","unstructured":"Smits-Seemann, RR, Kaul, S, Zamora, ER, Wu, YP, Kirchhoff, AC. Barriers to follow-up care among survivors of adolescent and young adult cancer. J\u00a0Cancer Surviv 2017;11:126\u201332. https:\/\/doi.org\/10.1007\/s11764-016-0570-3.","DOI":"10.1007\/s11764-016-0570-3"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_071","doi-asserted-by":"crossref","unstructured":"McCorkle, R, Ercolano, E, Lazenby, M, Schulman-Green, D, Schilling, LS, Lorig, K, et al.. Self\u2010management: enabling and empowering patients\u00a0living with cancer as a chronic illness. CA Cancer J Clin 2011;61:50\u201362. https:\/\/doi.org\/10.3322\/caac.20093.","DOI":"10.3322\/caac.20093"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_072","doi-asserted-by":"crossref","unstructured":"Travis, LB, Wahnefried, WD, Allan, JM, Wood, ME, Ng, AK. Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. Nat Rev Clin Oncol 2013;10:289\u2013301. https:\/\/doi.org\/10.1038\/nrclinonc.2013.41.","DOI":"10.1038\/nrclinonc.2013.41"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_073","doi-asserted-by":"crossref","unstructured":"Fidler, MM, Reulen, RC, Henson, K, Kelly, J, Cutter, D, Levitt, GA, et al.. Population-based long-term cardiac-specific mortality among 34\u00a0489\u00a0five-year survivors of childhood cancer in Great Britain. Circulation 2017;135:951\u201363. https:\/\/doi.org\/10.1161\/circulationaha.116.024811.","DOI":"10.1161\/CIRCULATIONAHA.116.024811"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_074","doi-asserted-by":"crossref","unstructured":"Barnett, M, McDonnell, G, DeRosa, A, Schuler, T, Philip, E, Peterson, L, et al.. Psychosocial outcomes and interventions among cancer survivors diagnosed during adolescence and young adulthood (AYA): a systematic review. J\u00a0Cancer Surviv 2017 2016;10:814\u201331. https:\/\/doi.org\/10.1007\/s11764-016-0527-6.","DOI":"10.1007\/s11764-016-0527-6"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_075","doi-asserted-by":"crossref","unstructured":"Hoppe, RT. Evolution of the techniques of radiation therapy in the management of lymphoma. Int J Clin Oncol 2013;18:359\u201363. https:\/\/doi.org\/10.1007\/s10147-013-0556-3.","DOI":"10.1007\/s10147-013-0556-3"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_076","doi-asserted-by":"crossref","unstructured":"Nanda, R, Flampouri, S, Mendenhall, NP, Indelicato, DJ, Jones, LM, Seeram, VK, et al.. Pulmonary toxicity following proton therapy for thoracic lymphoma. Int J Radiat Oncol Biol Phys 2017;99:494\u20137. https:\/\/doi.org\/10.1016\/j.ijrobp.2017.04.001.","DOI":"10.1016\/j.ijrobp.2017.04.001"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_077","doi-asserted-by":"crossref","unstructured":"Moreno, AC, Gunther, JR, Milgrom, S, Fuller, CD, Williamson, T, Liu, A, et al.. Effect of deep inspiration breath hold on normal tissue sparing with intensity modulated radiation therapy versus proton therapy for mediastinal lymphoma. Adv Radia Oncology 2020;5:1255\u201366. https:\/\/doi.org\/10.1016\/j.adro.2020.08.004.","DOI":"10.1016\/j.adro.2020.08.004"},{"key":"2026050116285907848_j_ijamh-2025-0131_ref_078","doi-asserted-by":"crossref","unstructured":"Dabaja, BS, Hoppe, BS, Plastaras, JP, Newhauser, W, Rosolova, K, Flampouri, S, et al.. Proton therapy for adults with mediastinal lymphomas: the international lymphoma radiation oncology group guidelines. Blood, The J American Society of Hemato 2018;132:1635\u201346. https:\/\/doi.org\/10.1182\/blood-2018-03-837633.","DOI":"10.1182\/blood-2018-03-837633"}],"container-title":["International Journal of Adolescent Medicine and Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/ijamh-2025-0131\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/ijamh-2025-0131\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T16:29:22Z","timestamp":1777652962000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/ijamh-2025-0131\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":78,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,10,16]]},"published-print":{"date-parts":[[2026,4,30]]}},"alternative-id":["10.1515\/ijamh-2025-0131"],"URL":"https:\/\/doi.org\/10.1515\/ijamh-2025-0131","relation":{},"ISSN":["2191-0278"],"issn-type":[{"value":"2191-0278","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]}}}